诱导性低温治疗脓毒性休克合并呼吸衰竭(CASS):随机对照开放标签试验
BACKGROUND: Animal models of serious infection suggest that 24 h of induced hypothermia improves circulatory and respiratory function and reduces mortality.…
要点
- 诱导性低温未降低脓毒性休克合并呼吸衰竭患者的 30 天死亡率。
- 低温组死亡率数值上高于常规体温管理组,但差异未达统计学显著。
- 脓毒性休克患者不应使用诱导性低温治疗。
核心结论
- 在脓毒性休克且依赖机械通气的呼吸衰竭患者中,诱导性低温不降低死亡率。
- 诱导性低温不应应用于脓毒性休克患者。
研究设计与样本
- 纳入标准:脓毒性休克或严重脓毒症、平均动脉压<70 mmHg、ICU 机械通气、年龄≥50 岁、预计 ICU 停留≥24 小时、符合标准后 6 小时内入组。
- 随机 1:1 分配至常规体温管理或 24 小时诱导性低温(目标 32–34°C)后 48 小时常温(36–38°C)。
- 主要终点为改良意向治疗人群的 30 天全因死亡率。
- 计划纳入 560 例,实际纳入 436 例后因无效提前终止(低温组 220 例,常规组 216 例)。
临床怎么用
- 脓毒性休克合并呼吸衰竭患者不应采用诱导性低温治疗。
- 常规体温管理仍是此类患者的适用策略。
局限性
- 试验因无效提前终止,实际样本量 436 例低于计划的 560 例。
- 干预实施者和患者未设盲,仅主要结局评估者设盲。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Animal models of serious infection suggest that 24 h of induced hypothermia improves circulatory and respiratory function and reduces mortality. We tested the hypothesis that a reduction of core temperature to 32-34°C attenuates organ dysfunction and reduces mortality in ventilator-dependent patients with septic shock. METHODS: In this randomised, controlled, open-label trial, we recruited patients from ten intensive care units (ICUs) in three countries in Europe and North America. Inclusion criteria for patients with severe sepsis or septic shock were a mean arterial pressure of less than 70 mm Hg, mechanical ventilation in an ICU, age at least 50 years, predicted length of stay in the ICU at least 24 h, and recruitment into the study within 6 h of fulfilling inclusion criteria. Exclusion criteria were uncontrolled bleeding, clinically important bleeding disorder, recent open surgery, pregnancy or breastfeeding, or involuntary psychiatric admission. We randomly allocated patients 1:1 (with variable block sizes ranging from four to eight; stratified by predictors of mortality, age, Acute Physiology and Chronic Health Evaluation II score, and study site) to routine thermal management or 24 h of induced hypothermia (target 32-34°C) followed by 48 h of normothermia (36-38°C). The primary endpoint was 30 day all-cause mortality in the modified intention-to-treat population (all randomly allocated patients except those for whom consent was withdrawn or who were discovered to meet an exclusion criterion after randomisation but before receiving the trial intervention). Patients and health-care professionals giving the intervention were not masked to treatment allocation, but assessors of the primary outcome were. This trial is registered with ClinicalTrials.gov, number NCT01455116. FINDINGS: Between Nov 1, 2011, and Nov 4, 2016, we screened 5695 patients. After recruitment of 436 of the planned 560 participants, the trial was terminated for futility (220 [50%] randomly allocated to hypothermia and 216 [50%] to routine thermal management). In the hypothermia group, 96 (44·2%) of 217 died within 30 days versus 77 (35·8%) of 215 in the routine thermal management group (difference 8·4% [95% CI -0·8 to 17·6]; relative risk 1·2 [1·0-1·6]; p=0·07]). INTERPRETATION: Among patients with septic shock and ventilator-dependent respiratory failure, induced hypothermia does not reduce mortality. Induced hypothermia should not be used in patients with septic shock. FUNDING: Trygfonden, Lundbeckfonden, and the Danish National Research Foundation.
引用
- Itenov TS, Johansen ME, Bestle M, et al. Induced hypothermia in patients with septic shock and respiratory failure (CASS): a randomised, controlled, open-label trial. Lancet Respir Med. 2018. PMID: 29325753. doi:10.1016/S2213-2600(18)30004-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。